Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
暂无分享,去创建一个
K. Mitani | N. Takahashi | S. Tanosaki | C. Nakaseko | K. Ohishi | H. Nishikawa | T. Fukuda | H. Wakita | F. Kimura | Y. Kameoka | K. Nishiwaki | C. Ohwada | N. Aotsuka | M. Tokuhira | Saori Takahashi | H. Kimura | J. Kuroki | K. Sano | O. Iwase | K. Fujikawa | Hideo Kimura
[1] K. Mitani,et al. Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan , 2018, International Journal of Hematology.
[2] J. Lipton,et al. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase , 2018, Annals of Internal Medicine.
[3] J. Cayuela,et al. Treatment-free remission in patients with chronic myeloid leukemia , 2018, International Journal of Hematology.
[4] T. Naoe,et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study , 2018, International Journal of Hematology.
[5] W. Wiktor-Jedrzejczak,et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study , 2017, Leukemia.
[6] M. Tulliez,et al. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] U. Olsson‐Strömberg,et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia , 2016, Leukemia.
[8] S. Mustjoki,et al. Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial , 2016 .
[9] T. Hughes,et al. Moving treatment-free remission into mainstream clinical practice in CML. , 2016, Blood.
[10] F. Mahon,et al. Deep molecular responses for treatment‐free remission in chronic myeloid leukemia , 2016, Cancer medicine.
[11] C. Chai-Adisaksopha,et al. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis , 2016, Leukemia & lymphoma.
[12] Sukjoong Oh,et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study , 2016, Haematologica.
[13] J. Richter,et al. The concept of treatment-free remission in chronic myeloid leukemia , 2016, Leukemia.
[14] I. Flinn,et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial , 2016, Leukemia.
[15] J. Sakamoto,et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. , 2015, The Lancet. Haematology.
[16] S. Redaelli,et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study , 2015, American journal of hematology.
[17] B. Leber,et al. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. , 2014, Blood.
[18] U. Olsson‐Strömberg,et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Cayuela,et al. Reply to J. Richter et al. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] N. Takahashi. Predictive factors of successful treatment-free remission for patients with chronic myeloid leukemia. , 2014, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[21] T. Yoshimoto,et al. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib , 2013, Cancer science.
[22] J. Melo,et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. , 2013, Blood.
[23] I. Flinn,et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up , 2012, Leukemia.
[24] T. Kyo,et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia , 2011, Haematologica.
[25] I. Flinn,et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. , 2011, The Lancet. Oncology.
[26] M. Deininger. Hematology: Curing CML with imatinib—a dream come true? , 2011, Nature Reviews Clinical Oncology.
[27] Philippe Rousselot,et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.